Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Novel Dry Powder of Hyaluronic Acid-Vancomycin Complex for Inhalation Useful on Pulmonary Infections Associated to Cystic Fibrosis

María Sol Magi
,
Yanina De Lafuente
,
Eride Quarta
ORCID logo ,
María Celeste Palena
,
Perla Ardiles
,
Paulina Laura Páez
ORCID logo ,
Fabio Sonvico
ORCID logo ,
Francesca Buttini
ORCID logo ,
Alvaro Jimenez-Kairuz
*
Version 1 : Received: 8 February 2024 / Approved: 9 February 2024 / Online: 12 February 2024 (04:53:10 CET)

A peer-reviewed article of this Preprint also exists.

Magi, M.S.; de Lafuente, Y.; Quarta, E.; Palena, M.C.; Ardiles, P.R.; Páez, P.L.; Sonvico, F.; Buttini, F.; Jimenez-Kairuz, A.F. Novel Dry Hyaluronic Acid–Vancomycin Complex Powder for Inhalation, Useful in Pulmonary Infections Associated with Cystic Fibrosis. Pharmaceutics 2024, 16, 436. Magi, M.S.; de Lafuente, Y.; Quarta, E.; Palena, M.C.; Ardiles, P.R.; Páez, P.L.; Sonvico, F.; Buttini, F.; Jimenez-Kairuz, A.F. Novel Dry Hyaluronic Acid–Vancomycin Complex Powder for Inhalation, Useful in Pulmonary Infections Associated with Cystic Fibrosis. Pharmaceutics 2024, 16, 436.

Abstract

Polyelectrolyte-drug complexes are interesting alternatives to improve unfavourable drugs properties. Vancomycin (VAN) is an antimicrobial used in the treatment of methicillin-resistant Staphylococcus aureus pulmonary infections in patients with cystic fibrosis. It is generally administered intravenously with high incidence of adverse side effects, which could be reduced by intrapulmonary administration. Currently, there are no commercially available inhalable formulations containing VAN. Thus, the present work focuses on the preparation and characterization of an ionic complex between hyaluronic acid (HA) and VAN with potential use as inhalable formulations. Particulate-solid HA-VAN25 complex by spray drying from an aqueous dispersion was obtained. FTIR spectroscopy and thermal analysis confirmed the ionic interaction between HA and VAN, while an amorphous diffraction pattern by X-ray was observed. The powder density, geometric size and morphology showed a suitable aerosolization and aerodynamic performance of the powder, indicating the capability of reaching the deep lung. An in vitro extended-release profile of VAN from the complex was obtained, exceeding 24 hours. Microbiological assays against methicillin-resistant and -sensitive reference strains of Staphylococcus aureus, showed that VAN preserves its antibacterial efficacy. In conclusion, HA-VAN25 exhibited interesting properties for the development of inhalable formulations with potential efficacy and safety advantages over conventional treatment.

Keywords

Vancomycin inhalable; cystic fibrosis; polyelectrolyte-drug complex; hyaluronic acid; pulmonary infection

Subject

Chemistry and Materials Science, Other

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.